Shanghai Serum Bio-Technology Co. Ltd. A
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sales of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.
Shanghai Serum Bio-Technology Co. Ltd. A (688163) - Total Liabilities
Latest total liabilities as of June 2025: CN¥28.69 Million CNY
Based on the latest financial reports, Shanghai Serum Bio-Technology Co. Ltd. A (688163) has total liabilities worth CN¥28.69 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Serum Bio-Technology Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Shanghai Serum Bio-Technology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Serum Bio-Technology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shanghai Serum Bio-Technology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Increase Technology Co Ltd Class A
SHE:300713
|
China | CN¥562.34 Million |
|
Isabella Bank Corporation
OTCQX:ISBA
|
USA | $2.03 Billion |
|
Nanjing Bestway Intelligent Control Technology Co. Ltd. A
SHE:301195
|
China | CN¥341.76 Million |
|
Nanjing Wondux Environmental Protection Technology Corp Ltd
SHG:688178
|
China | CN¥1.10 Billion |
|
Concrete Pumping Holdings Class A
NASDAQ:BBCP
|
USA | $589.75 Million |
|
Voxel S.A.
WAR:VOX
|
Poland | zł286.16 Million |
|
Yantai Yatong Precision Mechanical Corp. A
SHG:603190
|
China | CN¥1.70 Billion |
|
Dogu Aras Enerji Yatirimlari AS
IS:ARASE
|
Turkey | TL8.69 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Shanghai Serum Bio-Technology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 37.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Serum Bio-Technology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Serum Bio-Technology Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of Shanghai Serum Bio-Technology Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥24.53 Million | -42.45% |
| 2023-12-31 | CN¥42.63 Million | -4.96% |
| 2022-12-31 | CN¥44.86 Million | +34.86% |
| 2021-12-31 | CN¥33.26 Million | +0.35% |
| 2020-12-31 | CN¥33.15 Million | +17.66% |
| 2019-12-31 | CN¥28.17 Million | -- |